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From February through May of 1999, 13 cases of Influenza A virus (FLUAV), type H1N1 were reported at
a Department of Defense influenza surveillance sentinel site in Lima, Peru. Genetic and antigenic analysis
by hemagglutination inhibition and direct nucleotide sequencing of the HA1 region of the hemagglutinin
gene were performed on two isolates, A/Peru/1641/99 and A/Peru/1798/99. Both isolates were distinct
from the Bayern/7/95-like viruses circulating in the Americas and closely related to a Beijing/262/95-like
variant, A/New Caledonia/20/99. With the exception of travel-related cases, the detection of these isolates
represents the first appearance of New Caledonia/20/99-like viruses in the Americas. Since the character-
ization of these Peru isolates, a number of New Caledonia/20/99-like viruses have been reported world-
wide. For the 2000/01 and 2001/02 influenza seasons, the World Health Organization (WHO) has
recommended the inclusion of A/New Caledonia/20/99 as the H1N1 vaccine component for both the
southern and northern hemispheres. 
nfluenza epidemics occur in most parts of the world and
typically arise every 2 to 3 years, causing approximately
20,000 deaths above the yearly mortality baseline (1). The
incidence of recurring epidemics is primarily attributed to the
high frequency of mutational changes in the hemagglutinin
(HA) and neuraminidase (NA) major surface glycoproteins.
The hemagglutinin protein, responsible for viral uptake into
host epithelial cells, is also the antigen targeted by antibodies.
The HA1 subunit of the H1N1 hemagglutinin protein consists
of the globular head and contains five major antibody binding
sites: Sa, Sb, Ca1, Ca2, and Cb (2-5). Mutational changes (anti-
genic drift) at these four sites are thought to be driven by selec-
tive antibody pressure, which can produce novel strains
capable of evading the immunologic response. Monitoring the
antigenic drift of viruses in global populations is essential for
optimal selection of component strains for the annually
updated trivalent influenza vaccine.
Since 1976, the United States Air Force (USAF) has con-
tributed to influenza surveillance through a collaborative part-
nership with the Centers for Disease Control and Prevention
(CDC) and World Heath Organization (WHO) (6-7). In 1997,
the USAF expanded surveillance to include US Navy and
Army installations and became the Department of Defense
Global Emerging Infections System (DOD-GEIS) (6). The
DOD-GEIS influenza surveillance network receives samples
from training bases, ports of entry, and many military sentinel
sites in the United States, Pacific Rim, and Europe, and
throughout Central and South America. 
Since 1995, the predominant Influenza A viruses, type
H1N1 isolated in North and South America were closely
related to A/Bayern/7/95, while viruses belonging to another
genetic and antigenic lineage of H1N1 viruses, A/Beijing/262/
95, have remained geographically restricted to Asia (8-10).
During spring 1999, Beijing/262/95-like variants, containing a
characteristic deletion mutation at amino acid 134 of the HA
gene, were isolated from 13 persons at a DOD-GEIS influenza
surveillance site in Lima, Peru. These antigenically distinct
H1N1 viruses were closely related to A/New Caledonia/20/99,
a recently characterized variant from the Beijing/262/95 lin-
eage. Before these Peru isolates, no circulation of amino acid-
134 deletion mutants in the Americas was documented. 
Materials and Methods
Sources of Specimens
Influenza throat swab specimens were collected in accor-
dance with the case criteria outlined in Canas et al. (6). The
criteria included patients with a fever >37.8°C accompanied
by cough or sore throat. Throat swabs were taken within 72
hours of the onset of symptoms, placed in viral transport
media (MicroTest, M4) (VTM), and delivered via commercial
carrier to the clinical laboratory at the Epidemiological Sur-
veillance Division, Brooks Air Force Base. The two influenza
isolates used in this study were randomly selected from 13
positive patient samples isolated from February to April 1999
from a Department of Defense sentinel site in Lima, Peru. 
*Brooks Air Force Base, San Antonio, Texas, USA;  †Centers for Dis-
ease Control and Prevention, Atlanta, Georgia, USA
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Viral Detection
All influenza viruses examined in this study were passaged
one time through Primary Rhesus Monkey Kidney (PMK) tis-
sue culture (Viro-Med,  Minneapolis, MN; BioWhittaker,
Walkersville, MD). A total of 500 ml of VTM was injected
onto a shell vial containing a coverslip with PMK tissue cul-
ture. Cultures were tested for viral infection using the centrifu-
gation-enhanced shell-vial technique that includes a cell
monolayer grown on a coverslip contained in a shell vial.
Specimens are inoculated onto the cell monolayer, subjected to
a low speed centrifugation for 60 minutes, incubated at 35°C
for 48 hours to 72 hours and then screened with monoclonal
antibodies (Chemicon, Inc., Temecula, CA) to detect the pres-
ence of Influenza A or B viruses. Aliquots of all specimens
used in this study for the purposes of genetic analysis were
stored at -80°C until use. 
Antigenic and Genetic Typing
For antigenic analysis, aliquots of each isolate were sent
to CDC for characterization in hemagglutiniation inhibition
(HI) tests with postinfection ferret antisera as previously
described (11). 
For genetic typing, approximately 1 mL of VTM was used
to infect PMK tissue culture (Viro-Med,  Minneapolis, MN;
BioWhittaker, Walkersville, MD) and incubated at 37°C for 3
to 5 days. RNA was extracted from a 300 µl aliquot of tissue
culture fluid using the High Pure Viral RNA Kit (Boehringer-
Mannheim, Indianapolis, IN). Influenza RNA was amplified
into double stranded DNA by reverse transcription and poly-
merase chain reaction (RT-PCR) using the Titan One Step RT-
PCR Kit (Boehringer-Mannheim). An 1,187 bp cDNA frag-
ment consisting of the HA1 coding region of influenza A
hemagglutinin was amplified using forward primer F6-(5'-
AAGCAGGGGAAAATAAAA-3', mRNA) and reverse primer
R1193-(5'-GTAATCCCGTTAATGGCA-3', vRNA sense). The
RT-PCR reaction was performed by using a Perkin Elmer 2400
thermocycler (Forest City, CA). The PCR product was purified
using the QIAquick spin column purification (Qiagen, Valen-
cia, CA). Purified HA1 amplicon was cycle sequenced by
using the Big Dye Terminator Cycle Sequencing Kit (PE Bio-
systems) run on a 377-XL automated DNA sequencer accord-
ing to manufacturer recommendations (PE Biosystems). Four
internal oligonucleotide sequencing primers (Table 1) were
used to sequence the entire HA1 amplicon in both the forward
and reverse directions. Multiple sequence alignments, protein
translation, and phylogenetic analysis were performed by
using the software package Lasergene (version 3.18) (DNAS-
TAR, Madison, WI). The nucleotide and amino acid sequences
for A/Peru/1621/99 and A/Peru/1798/99 are available from
Genbank under the accession numbers AF268313 and
AF268312, respectively. Additional nucleotide and amino acid
sequences characterized by Brooks Air Force Base and
depicted in phylogenetic analysis are available from Genbank
under the accession numbers AY029287-AY029292.
Results
Antigenic Analysis
Antigenic characterization by HI, using postinfection ferret
antisera, was performed with reference antigens representing
two globally cocirculating Influenza A virus, type H1N1 anti-
genic/genetic lineages (A/Beijing/262/95, which includes the
variant A/New Caledonia/20/99; and A/Bayern/07/95, which
includes A/Johannesburg/82/96). Both Peru isolates were anti-
genically related to the A/Beijing/262/95 rather than to the A/
Bayern/07/95 lineage (Table 2). Both Peru isolates were anti-
genically close to the new variant, A/New Caledonia/20/99,
that recently evolved from the A/Beijing/262/95 virus. H1
titers of the Peru isolates were within a two-fold difference
from the homologous titer demonstrated by A/New Caledonia/
20/99 (160 vs. 320), while they were fourfold lower than the
A/Beijing/262/95 homologous titer (160 vs. 640).
Genetic Analysis
The complete nucleotide and deduced amino acid
sequences of the HA1 of the two Peru isolates were compared
with those of the previous vaccine strain, A/Beijing/262/95,
and the current vaccine strain, A/New Caledonia/20/99. Based
on nucleotide alignments, A/Peru/1621/99 and A/Peru/1798/
99 share identical HA1 sequences and are genetically closer
(97.9%) to A/New Caledonia/20/99 (97.9%) than they are to
Table 1. Characterization of Influenza A H1N1 (HA1) Sequencing 
Primers
Primer/nt 
position Sequence % GCb Tma(°C)
H1F-272 5′-AATCATGGTCCTACATTG-3′ 38.9 57
H1F-734 5′-ACTACTACTGGACTCTGC-3′ 50 58
H1R-365 5′-TTCCTCATACTCGGCGAA-3′ 50 58
H1R-1110 5′-CCATCCATCTATCATTCC-3′ 44.4 55
aTm= 81.5 + 16.6 * log [Na+] + 41 * (#G + #C)/length–500/length   
Where [Na+]= 0.1M.
bGC= (Guanosine (G) + Cytidine (C))/ (Adenosine (A)+ Thymidine (T)+ Guanosine 
(G) + Cytidine (C)) x 100
Table 2. Hemagglutination Inhibition Reactions of Influenza A(H1N1) 
Virusesa Reference Ferret Antisera
Reference Antigens Bei/262 NC/20 Bay/07 Joh/82
A/Beijing/262/95 640 320 20 20
A/New Caledonia/20/99 160 320 10 <10
A/Bayern/07/95 40 10 1280 1280
A/Johannesburg/82/96 40 10 1280 1280
Test Antigens
A/Peru/1621/99 160 160 <10 <10
A/Peru/1798/99 160 160 <10 <10
aTest viruses are considered antigenically similar to the reference strain if the H1 titer is 
equal or two times lower than the homologous titer of the reference virus. If the differ-
ence in H1 titers is 4-fold or higher, the test viruses are considered to be antigenically 
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the A/Bayern/07/95 (94.8%) or A/Beijing/262/95 (96.8%)
reference strains. 
A comparison of the amino acid residues of the Peru iso-
lates with A/New Caledonia/20/99 and A/Beijing/262/95 is
shown in Figure 1. The Peru isolates contained only 8 amino
acid differences compared with A/New Caledonia/20/99 and
11 amino acid differences compared with A/Beijing/262/95. A
substitution at residue 156(G156E) shows a neutral to acidic
amino acid change similar to those observed in some other
Beijing/262-like viruses. Amino acid substitutions at positions
190(N190D) and 194(L194I) are also characteristic of the
Beijing/262/95 lineage. Substitutions at position -1 (signal
sequence), 9, 82, 186, and 218 represent novel changes not
present in A/New Caledonia/20/99 or the majority of charac-
terized Beijing/262-like viruses.
A phylogenetic analysis (Figure 2) comparing the HA1
nucleotide sequence of the Peru isolates with H1N1 viruses
isolated after 1990 was performed with the software package
MegAlign (1993-1998) (DNASTAR, Madison, WI), using the
Jotun-Hein Method (12). Based on the topography, the Peru
isolates and other A/New Caledonia/20/99-like viruses iso-
lated by DOD-GIES during the 1999-2000 influenza season
appear to have evolved from Beijing/262/95-like viruses into a
distinct A/New Caledonia/20/99 sublineage. 
Discussion
A/Beijing/262/95-like viruses first appeared in China dur-
ing the 1994-95 influenza season and then spread throughout
Asia over the next 5 years (8-10). These viruses have a charac-
teristic deletion mutation in the HA molecule at residue 134.
In geographic areas outside Asia, Bayern/7/95-like viruses
have predominated during the 1996-97, 1997-98, and 1998-99
seasons (8-10). In May and June 1999, A/New Caledonia/20/
99, an antigenic variant of Beijing/262/95, was first reported in
New Caledonia in the Southern Pacific (13). Shortly thereafter,
A/New Caledonia/20/99-like viruses were detected throughout
South Africa and Asia. Isolates A/Peru/1621/99 and A/Peru/
1798/99 were collected during spring 1999. These isolates
were important because they were the first Beijing/262/95-like
viruses in the Americas with the signature HA1 deletion muta-
tion at residue 134. However, the Peru isolates were antigeni-
cally distinct from Beijing/262-like viruses and antigenically
similar to A/New Caledonia/20/99 (Table 2).
Figure 1. The amino acid sequence of the HA1 region of the hemagglutinin of the Peru isolates and A/Beijing/262/95 compared with the 2000/01
and 2001/02 vaccine strain, A/New Caledonia/20/99. Amino acid numbering corresponds to H3 subtype (19), with additional amino acids residues
present in the H1 subtype sequence indicated by an asterisk. Residue substitutions are shown. A dot (.) indicates amino acid homology to A/New
Caledonia/20/99.Emerging Infectious Diseases  •  Vol. 8, No. 4, April 2002 411
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Sequence comparisons further supported the results of the
antigenic analysis. Eleven amino acid differences in the HA1
protein were observed between the Peru isolates and A/
Beijing/262/95, the vaccine strain for the 1998-99 and 1999-
2000 influenza seasons. Four of these 11 substitutions were
located in 3 antigenic sites and could potentially alter anti-
body-binding properties of the viruses. Wilson and Cox pro-
posed that a drift variant of epidemiologic importance usually
contains four or more amino acid substitutions located in two
or more of the antigenic sites on the HA1 protein (14). Substi-
tutions at residues 218(A218T) and 225(G225D) were present
in the Ca antigenic site located approximately halfway down
the side of the HA1 globular head (3,15). Two other substitu-
tions, 82(E82D) and 166(N166K), were observed within anti-
genic sites Cb and Sa, located at the base and tip of the HA1
globular head, respectively (3,15).
Genetic comparisons between Peru isolates and A/New
Caledonia/20/99 show a difference of only eight amino acids
(Figure 1). Three of these eight residues, 156(E), 186(S), and
194(I), are present in the A/Beijing/262/95 vaccine strain. The
substitution at residue 190(D) is also typical for many Beijing/
262/95-like viruses, although not A/Beijing/262/95 itself (16).
The remaining four substitutions, at residues -1(L), 9(S),
82(D), and 218(T), are unique compared
with most recently characterized New
Caledonia/20/99 or A/Beijing/262/95-
like viruses. 
The phylogenetic analysis of Influ-
enza A viruses from 1990 to 2001 con-
firmed the coexistence of the two major
H1N1 lineages (Figure 2). The Beijing/
262/95-like lineage is easily distin-
guished from the Bayern/07/95-like
viruses by a characteristic deletion at
residue 134. With the exception of one
Bayern/07/95-like isolate, all the viruses
genetically characterized by DOD-GEIS
since these Peru isolates were detected
contain the residue 134-deletion muta-
tion and appear to be evolving from A/
Beijing/262/95 into a distinct sublineage
(Figure 2). The A/Peru/1621/99 and A/
Peru/1798/99 isolates are depicted as a
distinct branch in the phylogeny of New
Caledonia-like viruses. 
Since these Peru strains were first
identified in 1999, DOD-GEIS and CDC
have characterized similar New Cale-
donia/20/99-like viruses isolated from
throughout North and South America
during the 1999/2000 influenza season.
The sudden widespread appearance of
these viruses prompted WHO to recom-
mend the change to A/New Caledonia/
20/99 as the 2000/01 H1N1 influenza
vaccine component (13). This recommendation was timely
because the 1999/2000 vaccine containing the A/Beijing/262/
95 H1N1 component induced a cross-reactive response to A/
Bayern/7/95-like viruses but induced lower titers of antibodies
to A/New Caledonia/20/99-like strains (17). Therefore, a
change in the H1N1 component was necessary to ensure that
the vaccine would provide effective immunization against
emerging A/New Caledonia/20/99-like viruses. 
During the 2000/01 influenza season, New Caledonia-like
viruses continued to predominate over the H1N1 Bayern-like
lineage and were associated with outbreaks in many countries
(13, 18). During this season, DOD-GEIS characterized 83
influenza A H1N1 viruses. Of these, 80 (96%) were antigeni-
cally related to A/New Caledonia/20/99; three (4%) were Bay-
ern/7/95-like. Our antigenic data are consistent with findings
that approximately 84% of H1N1 viruses characterized by
CDC during the 2000/2001 influenza season were similar to
A/New Caledonia/20/99 (13, 18). The continued persistence of
New Caledonia-like viruses in the global population encour-
aged WHO to maintain A/New Caledonia/20/99 as the H1N1
component for the current 2001/2002 influenza season (20). 
Studies based on amino acid analyses of viruses from pre-
vious years to predict the evolution of future H1N1 epidemic
Figure 2. An unrooted phylogenetic analysis of the HA1 gene nucleotide sequence of influenza A
H1N1 viruses isolated since 1990. Peru isolates 1621 and 1798 are within the Beijing/262/95 lin-
eage but are more similar to A/New Caledonia/20/99. A number of isolates characterized by
Brooks Air Force Base from 1999 to 2001 were also A/NC/20/99-like. The tree was generated by
using the Jotun-Hein algorithm (6) in MegAlign software (version 3.18). Horizontal lines are pro-
portional to the number of substitutions between branch points. Asterisk (*) denotes 2000/01 vac-
cine strain; (1) denotes isolates characterized by Brooks Air Force Base. Brooks Air Force Base
isolates are available from Genbank under accession numbers AF268312, AF268313 and
AY029287-AY029292.RESEARCH
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strains would be advantageous as a surveillance tool and could
contribute to the vaccine selection process. Using a retrospec-
tive approach, Bush et al. determined that specific codons in
the HA1 domain of the hemagglutinin gene of human influ-
enza subtype H3 are under positive selection to mutate (21-
22). Certain amino acids in the HA1 of human H1N1 viruses
mutate at positively selected codons, giving rise to new viral
lineages. The characterization of these Peru variants empha-
sizes the need to be vigilant in examining sublineage amino
acid changes that may be indicators for the emergence of
future strains.
The effectiveness of an annually determined trivalent
influenza vaccine depends on choosing component strains that
offer optimal immunity from the numerous variants in global
circulation. In addition, timing is critical because the vaccine
strains are selected months before the onset of influenza sea-
son to ensure the production of adequate amounts of vaccine
by drug manufacturers. 
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